Advances in Severe Asthma Management

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Pathophysiology of Severe Asthma

Asthma and Healthcare Utilization

Inflammatory Mechanisms in Severe Asthma Type 2 Inflammation

Downstream Mediators Trigger Type 2 Asthma

Mast Cells

Current Therapeutic Targets

Future Targets for Therapies

Concluding Remarks

Managing Severe Asthma in Patients With Comorbid Type 2 Diseases

Asthma-Associated Comorbidities

Type 2 Comorbidities and Asthma Exacerbations

Allergic Rhinitis Prevalence in Asthma

Allergic Rhinitis Clinical Presentation

Chronic Rhinosinusitis

Nasal Polyps

GERD

Atopic Dermatitis

Biologics for the Treatment of Type 2 Comorbidities

Dupilumab Treatment of CRSwNP

Dupilumab Treatment of AR

Concluding Remarks

Use of Biomarkers to Tailor Therapy for Severe Asthma

Biomarkers

Biomarkers in Asthma

Biomarkers in Asthma (Cont.)

Eosinophils

FeNO

Periostin Possible Future Biomarker

Concluding Remarks

Data on Long-Term Treatment With Targeted Therapies

Approved Targeted Therapies Severe Asthma

Omalizumab EXTRA Study

Mepolizumab SIRIUS Study

Benralizumab ZONDA Study

Phenotypes and Biomarkers Putting Knowledge Into Practice

Patient Considerations for Treatment

Emerging Data on Biologic Therapies for Severe Asthma

Targets for Investigational Treatments

Dupilumab

Dupilumab Phase 3: Quest Study

QUEST Study Results

QUEST Study Results (Cont)

VENTURE Study

VENTURE Study Results

Dupilumab Safety Data

TSLP

Tezepelumab

Fevipiprant

Concluding Remarks

Abbreviations

Abbreviations (cont)

Abbreviations (cont)